journal
MENU ▼
Read by QxMD icon Read
search

Pharmaceutical Patent Analyst

journal
https://www.readbyqxmd.com/read/28201948/enbrel-and-etanercept-biosimilars-a-tale-of-two-patent-systems
#1
Peter Norman
No abstract text is available yet for this article.
February 16, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28198642/upcoming-challenges-in-intellectural-property-presented-by-emerging-pharmaceutical-technologies
#2
Takeshi S Komatani
No abstract text is available yet for this article.
February 15, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28181455/how-cuozzo-will-impact-the-interplay-between-post-grant-proceedings-and-hatch-waxman-litigation
#3
Natasha Mishra, Patrick A Doody, Raj S Davé
No abstract text is available yet for this article.
February 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28155581/patent-highlights-august-september-2016
#4
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
February 3, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28155578/novel-linkers-and-connections-for-antibody-drug-conjugates-to-treat-cancer-and-infectious-disease
#5
Thomas H Pillow
Antibody-drug conjugates (ADCs) are an exciting therapeutic, combining the extreme potency of a small molecule cytotoxic drug with the exquisite selectivity of a monoclonal antibody. Despite the promising concept and many decades of research and clinical experiments, only two ADCs are approved for human use. Among the lessons learned, have been the need for highly stable and potentially releasable linkers and the empirical nature of therapeutic index supporting the testing of many diverse cytotoxics, many requiring new linker connections for the drug's available functional groups...
February 3, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28155570/pharmaceutical-patent-protection-the-united-states-and-japan-in-comparative-perspective
#6
Shinya Kimura, Carlyn A Burton
No abstract text is available yet for this article.
February 3, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27848274/is-inherent-disclosure-sufficient-for-priority-claim-monoclonal-versus-chimeric-humanized-antibody-estoppels
#7
Takeshi S Komatani
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27813447/fostering-innovative-product-development-for-neglected-tropical-diseases-through-partnerships
#8
Amy Starr, Katy M Graef, Jennifer Dent
Neglected tropical diseases are a group of infectious diseases that threaten and impact a significant portion of individuals living in low- and middle-income countries. Healthcare product R&D, which has been relatively limited for this group of infectious diseases, is timely and requires significant risk and resource investment by companies. Regardless of these costs, the global community has recognized the impact on human health that developing products for these diseases could have. Incentives, including 'push' and 'pull' funding, and platforms that support sharing of intellectual property through partnerships, such as The World Intellectual Property Organization Re:Search, are driving R&D...
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27813443/validity-studies-enhancing-patent-searches
#9
Sophie Bergeron, James L Grant
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27805847/compulsory-licensing-of-patents-in-india
#10
Rahul Chaudhry
This article deals with compulsory licensing scenarios in India, provides a background of relevant provisions in the Patents Act and examines how these provisions are Trade-Related Aspects of Intellectual Property Rights compliant. This article further discusses the procedure followed by India in granting a compulsory license, provides an overview of compulsory license applications filed in India to date and judicial precedence regarding the same. This article also highlights how compulsory licensing is a great safeguard that balances the interests of the innovators and the public at large...
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27805846/patent-highlights-june-july-2016
#11
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27805479/compulsory-licenses-as-a-defense-in-pharmaceutical-and-biotech-patent-litigation
#12
Andreas von Falck
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27804787/pharmaceutical-patent-applications-in-freeze-drying
#13
Edmond Ekenlebie, Tomaž Einfalt, Arianna Irò Karytinos, Andrew Ingham
Injectable products are often the formulation of choice for new therapeutics; however, formulation in liquids often enhances degradation through hydrolysis. Thus, freeze-drying (lyophilization) is regularly used in pharmaceutical manufacture to reduce water activity. Here we examine its contribution to 'state of the art' and look at its future potential uses. A comprehensive search of patent databases was conducted to characterize the international patent landscape and trends in the use of freeze-drying. A total of 914 disclosures related to freeze-drying, lyophilization or drying of solid systems in pressures and temperatures equivalent to those of freeze-drying were considered over the period of 1992-2014...
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27804785/crowdsourcing-in-pharmaceutical-r-d-a-revolutionary-concept-or-nothing-new
#14
Chie Hoon Song
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27804784/update-on-brazil-s-pharma-patent-landscape
#15
Rana Gosain
Brazil's Pharma market is a dynamic and promising one. It ranks within the top ten market. There are peculiar hurdles that patentees have to overcome, such as, a two-tier examination, a serious backlog at the Brazilian Patent and Trademark Office. Several measures to accelerate examination have been adopted given the meager number of Examiners.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27804782/creating-commercial-value-from-patents-the-interplay-between-patent-protection-and-patent-information-management
#16
Chie Hoon Song
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27610753/fluorine-18-patents-2009-2015-part-2-new-radiochemistry
#17
Andrew V Mossine, Stephen Thompson, Allen F Brooks, Alexandra R Sowa, Jason M Miller, Peter Jh Scott
Fluorine-18 ((18)F) is one of the most common positron-emitting radionuclides used in the synthesis of positron emission tomography radiotracers due to its ready availability, convenient half-life and outstanding imaging properties. In Part 1 of this review, we presented the first analysis of patents issued for novel radiotracers labeled with fluorine-18. In Part 2, we follow-up with a focus on patents issued for new radiochemistry methodology using fluorine-18 issued between January 2009 and December 2015.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27610752/surface-modulatable-nanocapsids-for-targeting-and-tracking-toward-nanotheranostic-delivery
#18
Marie Stark, R Holland Cheng
Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery...
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27573248/plausibility-in-patent-law-an-unsettled-concept
#19
Constance Crawford, Laura Reynolds
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/27573095/how-the-new-patent-trial-and-appeal-board-rules-impact-the-practice-of-inter-partes-reviews
#20
Benjamin C Hsing, Wanda French-Brown
No abstract text is available yet for this article.
September 2016: Pharmaceutical Patent Analyst
journal
journal
47821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"